glp-1 receptor agonists should be avoided in patients with GI Adverse Effects of Glucagon-Like Peptide-1 Dietary intake by patients taking

The lower incidence of breast cancer was seen across both cohorts: 35.1 percent lower odds in the full analysis and 30.5 percent lower odds in the matched cohort

A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves the Gastrointestinal tolerability of glucagon-like peptide-1 receptor agonist therapy

[DOI] [PMC free article] [PubMed] [Google Scholar] 41.Chapman M.B., Norwood D.A., Price C., et al

A prespecified analysis of pooled data from the STEP-HFpEF and STEP-HFpEF DM trials demonstrated that significantly more patients treated with Wegovy 2.4 mg SC once weekly had an improvement of at least one in New York Heart Association (NYHA) functional class compared to those who received placebo (32.6% versus 21.5%, respectively